Remove Cardiomyopathy Remove Defibrillator Remove Sudden Cardiac Death
article thumbnail

Amiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy

JAMA Cardiology

This randomized clinical trial assesses whether cardioverter-defibrillator implantation is more effective than amiodarone therapy for the primary prevention of all-cause mortality and secondary prevention of sudden cardiac death, hospitalization for heart failure, and use of a pacemaker among patients with chronic Chagas cardiomyopathy.

article thumbnail

Heart Vest Could Help Predict Sudden Cardiac Death Risk

DAIC

Image courtesy of UCL Institute of Cardiovascular Science / James Tye milla1cf Tue, 12/19/2023 - 18:19 December 19, 2023 — A vest that can map the electrical activity of the heart in fine detail could potentially be used to better identify people at high risk of sudden cardiac death , suggests a new study led by UCL researchers.

article thumbnail

PO-02-167 FACTORS IMPACTING SHOCK IMPEDANCE IN SUBCUTANEOUS IMPLANTABLE-CARDIOVERTER DEFIBRILLATORS IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY

HeartRhythm

Hypertrophic cardiomyopathy (HCM) is associated with risk of sudden cardiac death (SCD). Since approval in late 2012, the subcutaneous implantable cardioverter-defibrillator (SICD) has been used as an alternative to the traditional transvenous ICD (TV-ICD) for SCD prevention in HCM.

article thumbnail

MP-470545-006 TEN-YEAR EXPERIENCE OF THE SUBCUTANEOUS IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY

HeartRhythm

Hypertrophic cardiomyopathy (HCM) is associated with risk of sudden cardiac death (SCD). Since approval in late 2012, the subcutaneous implantable cardioverter-defibrillator (SICD) has been used as an alternative to the traditional transvenous ICD (TV-ICD) for SCD prevention in HCM.

article thumbnail

Efficacy of Catheter Ablation for Ventricular Tachycardia in Ischemic Cardiomyopathy Patients without an ICD Implantation

HeartRhythm

Implantable cardioverter defibrillator (ICD) prevents sudden cardiac death (SCD) in patients with ischemic cardiomyopathy (ICM). Catheter ablation has been shown to effectively reduce ventricular tachycardia (VT) recurrence, yet its efficacy in patients without an ICD implantation remains uncertain.

article thumbnail

MP-470549-001 RIGHT VENTRICULAR FUNCTION AS PREDICTOR OF APPROPRIATE ICD THERAPY IN PATIENTS WITH NONISCHEMIC CARDIOMYOPATHY FOR PRIMARY PROPHYLAXIS

HeartRhythm

Predictive factors of benefit from implantation of an implantable cardioverter-defibrillator (ICD) for primary prophylaxis of sudden cardiac death in patients with nonischemic cardiomyopathy (NICM) have not been clarified.

article thumbnail

Abstract 4142952: Feature Tracking Global Longitudinal Strain in Long-term Risk Stratification of Hypertrophic Cardiomyopathy without Septal Reduction Therapy

Circulation

In the subgroup with Class 3 of recommendation for implantable cardioverter defibrillator, patients with absolute LV-GLS ≤ 9% showed significantly worse prognosis than those with absolute LV-GLS > 9% (p =.002 Circulation, Volume 150, Issue Suppl_1 , Page A4142952-A4142952, November 12, 2024. vs -266.2; vs -264.9; 009), respectively.